GAMCO Investors’s AbbVie ABBV Stock Holding History

GAMCO Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.29M	Sell	15,124 -128	-0.8%	-$28.4K	0.03%	443
2025 Q4	$3.48M	Sell	15,252 -16	-0.1%	-$3.65K	0.03%	437
2025 Q3	$3.54M	Sell	15,268 -482	-3%	-$98.2K	0.03%	421
2025 Q2	$2.92M	Buy	15,750 +2,402	+18%	+$446K	0.03%	468
2025 Q1	$2.8M	Sell	13,348 -189	-1%	-$36.7K	0.03%	444
2024 Q4	$2.41M	Sell	13,537 -76	-0.6%	-$14K	0.03%	475
2024 Q3	$2.69M	Sell	13,613 -1,138	-8%	-$212K	0.03%	456
2024 Q2	$2.53M	Buy	14,751 +475	+3%	+$78.7K	0.03%	458
2024 Q1	$2.6M	Sell	14,276 -955	-6%	-$165K	0.03%	450
2023 Q4	$2.36M	Sell	15,231 -1,024	-6%	-$149K	0.03%	468
2023 Q3	$2.42M	Sell	16,255 -15	-0.1%	-$2.2K	0.03%	442
2023 Q2	$2.19M	Sell	16,270 -3,147	-16%	-$461K	0.02%	465
2023 Q1	$3.09M	Sell	19,417 -665	-3%	-$102K	0.03%	403
2022 Q4	$3.25M	Buy	20,082 +498	+3%	+$76.4K	0.03%	385
2022 Q3	$2.63M	Buy	19,584 +1,342	+7%	+$193K	0.03%	425
2022 Q2	$2.79M	Sell	18,242 -911	-5%	-$139K	0.03%	415
2022 Q1	$3.1M	Sell	19,153 -1,683	-8%	-$244K	0.03%	423
2021 Q4	$2.82M	Sell	20,836 -3,916	-16%	-$463K	0.02%	451
2021 Q3	$2.67M	Buy	24,752 +3,122	+14%	+$357K	0.02%	459
2021 Q2	$2.44M	Buy	21,630 +67	+0.3%	+$7.55K	0.02%	489
2021 Q1	$2.33M	Buy	21,563 +813	+4%	+$87K	0.02%	482
2020 Q4	$2.22M	Sell	20,750 -7,095	-25%	-$682K	0.02%	463
2020 Q3	$2.44M	Sell	27,845 -12,384	-31%	-$1.17M	0.03%	430
2020 Q2	$3.95M	Buy	40,229 +9,401	+30%	+$828K	0.04%	346
2020 Q1	$2.35M	Buy	30,828 +4,821	+19%	+$411K	0.03%	398
2019 Q4	$2.3M	Buy	26,007 +589	+2%	+$48.9K	0.02%	476
2019 Q3	$1.93M	Buy	25,418 +15,435	+155%	+$1.06M	0.02%	499
2019 Q2	$726K	Buy	9,983 +1,219	+14%	+$95.8K	0.01%	661
2019 Q1	$706K	Buy	8,764 +864	+11%	+$70.7K	0.01%	629
2018 Q4	$728K	Buy	7,900 +150	+2%	+$13.2K	0.01%	590
2018 Q3	$733K	Sell	7,750 -10,435	-57%	-$990K	0.01%	629
2018 Q2	$1.69M	Sell	18,185 -452	-2%	-$44.1K	0.01%	508
2018 Q1	$1.76M	Sell	18,637 -70	-0.4%	-$7.69K	0.01%	490
2017 Q4	$1.81M	Sell	18,707 -141	-0.7%	-$13.3K	0.01%	505
2017 Q3	$1.68M	Sell	18,848 -425	-2%	-$32.4K	0.01%	512
2017 Q2	$1.4M	Sell	19,273 -103	-0.5%	-$6.92K	0.01%	534
2017 Q1	$1.26M	Sell	19,376 -700	-3%	-$44K	0.01%	551
2016 Q4	$1.26M	Sell	20,076 -120	-0.6%	-$7.33K	0.01%	546
2016 Q3	$1.27M	Sell	20,196 -15,100	-43%	-$978K	0.01%	542
2016 Q2	$2.19M	Sell	35,296 -164	-0.5%	-$9.99K	0.01%	494
2016 Q1	$2.02M	Sell	35,460 -5,140	-13%	-$286K	0.01%	496
2015 Q4	$2.4M	Sell	40,600 -3,330	-8%	-$192K	0.02%	464
2015 Q3	$2.39M	Sell	43,930 -2,632	-6%	-$171K	0.02%	485
2015 Q2	$3.13M	Sell	46,562 -650	-1%	-$42.4K	0.02%	462
2015 Q1	$2.76M	Buy	47,212 +12,655	+37%	+$765K	0.01%	490
2014 Q4	$2.26M	Buy	34,557 +24,175	+233%	+$1.52M	0.01%	520
2014 Q3	$600K	Hold	10,382	–	–	﹤0.01%	711
2014 Q2	$586K	Sell	10,382 -80	-0.8%	-$4.2K	﹤0.01%	721
2014 Q1	$538K	Buy	10,462 +382	+4%	+$19.3K	﹤0.01%	704
2013 Q4	$532K	Hold	10,080	–	–	﹤0.01%	681
2013 Q3	$451K	Hold	10,080	–	–	﹤0.01%	704
2013 Q2	$417K	Buy	+10,080	New	+$441K	﹤0.01%	685

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GAMCO Investors's ABBV Position: Q1 2026 in Review

GAMCO Investors reduced its AbbVie (ABBV) stake by 0.84% in Q1 2026, selling an estimated $28.4K and leaving 15,124 shares worth $3.29M. The position accounts for 0.03% of the portfolio, ranked #443.

GAMCO Investors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.95M in Q2 2020. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

GAMCO Investors held 15,124 shares of AbbVie worth $3.29M as of Q1 2026.
GAMCO Investors sold 128 AbbVie shares in Q1 2026, an estimated $28.4K.
AbbVie made up 0.03% of GAMCO Investors's portfolio in Q1 2026, its #443 holding.
GAMCO Investors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
GAMCO Investors's AbbVie position peaked at $3.95M in Q2 2020.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on GAMCO Investors's 13F filing for Q1 2026, filed 14 May 2026.